Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stroke patients may get a second chance with early tirofiban

NCT ID NCT05604638

Disease control Sponsor: Second Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving the drug tirofiban soon after the standard clot-busting drug tenecteplase can help people recover better from a stroke. About 348 adults who had a stroke and received tenecteplase will be enrolled. The goal is to see if this combination reduces disability and improves daily function without increasing risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 348 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old; 2. Within 4-24 hours after intravenous thrombolytic therapy with tenerplase for acute ischemic stroke, there was no significant change in symptoms compared to the baseline (defined as an increase or decrease of 0 or 1 point in the NIHSS score), and neurological function deteriorated (defined as an increase of ≥ 2 in the NIHSS score compared to the baseline) Fluctuations in neurological function (defined as an increase of 4 points or more in the NIHSS score compared to the baseline and then a decrease of 4 points or more); 3. NIHSS ≥ 4 points before randomization; 4. The patient or their family members sign a written informed consent form. Exclusion Criteria: 1. Intracranial hemorrhage was confirmed by CT or MRI after intravenous thrombolysis and before randomization; 2. CTA/MRA/DSA showed occlusion of the internal carotid artery, middle cerebral artery M1, M2 or M3 segment, anterior cerebral artery A1, A2 or A3 segment, posterior cerebral artery P1, P2 or P3, vertebral or basilar artery; 3. Confirmed or suspected cardioembolic stroke mechanisms, including any of the following: documented cardiac sources of thromboembolism: chronic or paroxysmal atrial fibrillation, rheumatic mitral stenosis, prosthetic heart valves, infective endocarditis, intracardiac thrombus or implanted prosthetic material, dilated cardiomyopathy (left ventricular ejection fraction \<40%), or spontaneous echo contrast in the left atrium; other laboratory-confirmed embolic sources: patent foramen ovale with concomitant atrial septal aneurysm, or cryptogenic stroke with a CHADS-VASC score ≥ 2 indicating high thromboembolic risk; 4. Blood platelet count was lower than 100×10\^9/L; 5. Renal insufficiency, glomerular filtration rate \< 30 mL/min; 6. Pregnant or lactating women; 7. Allergic to tirofiban, nickel, titanium or their alloys; 8. Prior neurological or psychiatric illness that prevents assessment of neurological function; 9. Pre-existing bleeding disease, severe heart, liver, or kidney disease, or sepsis; 10. Brain tumors with a space-occupying effect on imaging (other than micromeningiomas); 11. Intracranial aneurysm, arteriovenous malformation; 12. Life expectancy of any advanced disease \< 6 months; 13. Participating in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jiujiang University

    RECRUITING

    Jiujiang, Jiangxi, China

  • Dalian Municipal Central Hospital

    RECRUITING

    Dalian, Liaoning, China

  • Ganzhou Municipal Hospital

    RECRUITING

    Ganzhou, Jiangxi, China

  • Ganzhou People's Hospital

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • Huangmei People's Hospital

    RECRUITING

    Huanggang, Hubei, China

  • Hunan University of Medicine Affiliated Pingjiang Hospital

    RECRUITING

    Yueyang, Hunan, China

  • Hunan Xupu Chengnan Hospital

    RECRUITING

    Huaihua, Hunan, China

  • Ji'an Central People's Hospital

    RECRUITING

    Ji’an, Jiangxi, China

  • Jiangxi Provincial People's Hospital

    RECRUITING

    Nanchang, Jiangxi, China

  • Longyan People´s Hospital, Longyan City

    RECRUITING

    Longyan, Fujian, China

  • Mingguang People's Hospital

    RECRUITING

    Chuzhou, Anhui, China

  • Nankang TCM Hospital

    RECRUITING

    Ganzhou, Jiangxi, China

  • People's Hospital Of Shaodong

    RECRUITING

    Shaoyang, Hunan, China

  • People's Hospital of Anyuan County

    RECRUITING

    Ganzhou, Jiangxi, China

  • People's Hospital of Chongyi County

    RECRUITING

    Ganzhou, Jiangxi, China

  • People's Hospital of Dayu County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Ganxian District

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Quannan County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of RuiJin City

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Shangyou County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Shicheng County

    RECRUITING

    Ganzhou, Jiangxi, China

  • People's Hospital of Wan'an county

    RECRUITING

    Ji’an, Jiangxi, China

  • People's Hospital of Xinfeng County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Xunwu County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • People's Hospital of Yichun

    RECRUITING

    Yichun, Jiangxi, China

  • People's Hospital of Yudu County

    RECRUITING

    Ganzhou, Jiangxi, 341000, China

  • Second Hospital of Xingguo County

    RECRUITING

    Ganzhou, Jiangxi, China

  • Second People's Hospital of Yudu County

    RECRUITING

    Ganzhou, Jiangxi, China

  • Shaoshan People's Hospital

    RECRUITING

    Xiangtan, Hunan, China

  • Songyuan Jilin Oilfield Hospital

    RECRUITING

    Songyuan, Jilin, China

  • The People's Hospital of Ningdu County

    RECRUITING

    Ganzhou, Jiangxi, China

  • The Second Affiliated Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, China

  • Traditional Chinese Medicine Hospital of Xingguo County

    RECRUITING

    Ganzhou, Jiangxi, China

  • Traditional Chinese Medicine Hospital of Yudu County

    RECRUITING

    Ganzhou, Jiangxi, China

  • Xiangtan Central Hospitall

    RECRUITING

    Xiangtan, Hunan, China

  • Yiling People's Hospital of Yichang city

    RECRUITING

    Yichang, Hubei, China

  • Yingtan People's Hospital

    RECRUITING

    Yingtan, Jiangxi, China

  • Zhongmeng Hospital of Hexigten Banner

    RECRUITING

    Chifeng, Neimenggu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.